缬沙坦联合硝苯地平缓释片治疗原发性高血压的临床疗效

刘晓侠

缬沙坦联合硝苯地平缓释片治疗原发性高血压的临床疗效

刘晓侠

目的 探讨缬沙坦联合硝苯地平缓释片治疗原发性高血压的临床疗效。方法 选择2015年1～12月在我院治疗的原发性高血压患者60例的临床资料进行回顾性分析。其中30例患者采用硝苯地平缓释片治疗为对照组，30例患者采用缬沙坦联合硝苯地平缓释片治疗为研究组。比较两组的临床疗效。结果 研究组总有效率高于对照组，差异有统计学意义（χ2=4.706，P＜0.05）。两组治疗后收缩压及舒张压均低于治疗前，差异有统计学意义（P＜0.05）；治疗后，研究组患者收缩压及舒张压均低于对照组，差异有统计学意义（t=2.579，6.850，P＜0.05）。对照组不良反应发生率高于研究组，差异有统计学意义（χ2=4.565，P＜0.05）。结论 缬沙坦联合硝苯地平缓释片治疗原发性高血压具有较好的临床疗效。

缬沙坦；硝苯地平缓释片；原发性高血压

【Abstract】

Objective To discuss clinical effects of valsartan combined with Nifedipine Delayde-release Tablets in the treatment of primary hypertension. Methods Clinical data of 60 cases with primary hypertension from Jan to Dec 2015 were respectively analyzed. 30 cases of study group were treated with valsartan combined with Nifedipine Delayde-release Tablets，and 30 cases of control group were treated with extended release Nifedipine tablets. Clinical efficacy of two groups was compared. Results Total effective rate of study group was higher than control group（χ2=4.706，P＜ 0.05）. SBP and DBP of two groups after treatment were lower than those before treatment，and the difference was statistically significant（P＜ 0.05）. After treatment，SBP and DBP of study group were lower than control group，and the difference was statistically significant（t=2.579，6.850，P＜ 0.05）. Incidence of adverse reactions of control group was higher than study group，and the difference was statistically significant（χ2=4.565，P＜ 0.05）. Conclusion Valsartan combined with extended release Nifedipine tablets in the treatment of primary hypertension shows good efficacy.

【Key words】Valsartan，Nifedipine delayde-release tablets，Primary hypertension

高血压是心脑血管疾病重要的病因及危险因素，影响重要器官的结构与功能，并最终导致这些器官衰竭。高血压与遗传、环境等因素有关，发病机制还不明确，是在遗传基础上多种危险因素作用的结果［1］。目前的治疗主要为血压控制，避免长期高血压对重要脏器的损害。缬沙坦是血管紧张素Ⅱ（AT）受体拮抗剂，具有控制血压的作用［2］。硝苯地平具有抑制Ca2+内流作用，可以用于各种类型高血压的治疗［3］。我们联合缬沙坦及硝苯地平缓释片治疗原发性高血压，取得了较好的效果，现将结果报道如下。

1　资料与方法

1.1一般资料

选择2015年1～12月在我院治疗的原发性高血压患者60例的临床资料进行回顾性分析。……